X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia

Core Insights - X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on its primary asset, Mavorixafor, which is commercially branded as Xolremdi and approved in the US for WHIM syndrome [1] Group 1 - The treatment Xolremdi is currently in the process of expanding its indications beyond WHIM syndrome [1]